| Literature DB >> 31703458 |
Yucai Chen1, Di Chen2, Sijia Liu1, Tianyi Yuan2, Jian Guo1, Lianhua Fang2, Guanhua Du2.
Abstract
: Numerous studies have shown that genistein has a good therapeutic effect on pulmonary hypertension (PH). However, there has been no systematic research performed yet to elucidate its exact mechanism of action in relation to PH. In this study, a systemic pharmacology approach was employed to analyze the anti-PH effect of genistein. Firstly, the preliminary predicted targets of genistein against PH were obtained through database mining, and then the correlation of these targets with PH was analyzed. After that, the protein-protein interaction network was constructed, and the functional annotation and cluster analysis were performed to obtain the core targets and key pathways involved in exerting the anti-PH effect of genistein. Finally, the mechanism was further analyzed via molecular docking of genistein with peroxisome proliferator-activated receptor γ (PPARγ). The results showed that the anti-PH effect of genistein may be closely related to PPARγ, apoptotic signaling pathway, and the nitric oxide synthesis process. This study not only provides new insights into the mechanism of genistein against PH, but also provides novel ideas for network approaches for PH-related research.Entities:
Keywords: genistein; molecular docking; network pharmacology; peroxisome proliferator-activated receptor γ (PPARγ); pulmonary hypertension
Year: 2019 PMID: 31703458 PMCID: PMC6888439 DOI: 10.3390/ijms20225569
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Molecular properties of genistein.
| Property | Parameter |
|---|---|
| MW | 270.24 g/mol |
| PSA | 87 ^A |
| XLogP3-AA | 2.7 |
| H-bond donor | 3 |
| H-bond acceptor | 5 |
| Rotatable bond count | 1 |
| ADMET Absorption Level | 0 |
| BBB Level | 3 |
MW: molecular weight; PSA: polar surface area; XLogP3-AA: computed octanol/water partition coefficient; BBB Level: blood brain barrier level.
VarElect analysis of targets of genistein with the “pulmonary hypertension” phenotype.
| NO. | Symbol | Description | Phenotypic Correlation | Score |
|---|---|---|---|---|
| 1 | NOS3 | Nitric Oxide Synthase 3 | Directly | 20.12 |
| 2 | NOS2 | Nitric Oxide Synthase 2 | Directly | 16.1 |
| 3 | VEGFA | Vascular Endothelial Growth Factor A | Directly | 11.77 |
| 4 | TNF | Tumor Necrosis Factor | Directly | 10.34 |
| 5 | PTGS2 | Prostaglandin-Endoperoxide Synthase 2 | Directly | 8.69 |
| 6 | ELANE | Elastase, Neutrophil Expressed | Directly | 8.53 |
| 7 | CCL2 | C-C Motif Chemokine Ligand 2 | Directly | 7.54 |
| 8 | PPARG | Peroxisome Proliferator Activated Receptor Gamma | Directly | 7.45 |
| 9 | IL1B | Interleukin 1 Beta | Directly | 6.44 |
| 10 | EGFR | Epidermal Growth Factor Receptor | Directly | 3.69 |
| 11 | MIF | Macrophage Migration Inhibitory Factor | Directly | 3.57 |
| 12 | TP53 | Tumor Protein P53 | Directly | 3.16 |
| 13 | AKT1 | AKT Serine/Threonine Kinase 1 | Directly | 2.53 |
| 14 | CASP3 | Caspase 3 | Directly | 2.38 |
| 15 | MAPK1 | Mitogen-Activated Protein Kinase 1 | Directly | 1.98 |
| 16 | HSP90AA1 | Heat Shock Protein 90 Alpha Family Class A Member 1 | Directly | 1.91 |
| 17 | HMGCR | 3-Hydroxy-3-Methylglutaryl-CoA Reductase | Directly | 1.83 |
| 18 | MME | Membrane Metalloendopeptidase | Directly | 0.64 |
| 19 | MAPK3 | Mitogen-Activated Protein Kinase 3 | Directly | 0.58 |
| 20 | BCL2 | BCL2, Apoptosis Regulator | Directly | 0.29 |
| 21 | MAPK14 | Mitogen-Activated Protein Kinase 14 | InDirectly | 8.24 |
| 22 | ADORA2A | Adenosine A2a Receptor | InDirectly | 3.27 |
The intersection genes are divided into two parts that are directly related and indirectly related to “pulmonary hypertension”. The level of the score indicates the correlation between genes and the target phenotype.
Figure 1Network of potential targets of genistein against PH analyzed by GeneMANIA. Genes on the inner ring were submitted as query terms in searches. Nodes on the outer ring indicate genes associated with query genes. Functional association of targets was analyzed, and different color of connecting lines represent different correlations.
Figure 2Gene Ontology (GO) analysis and Reactome pathway analysis of genistein targets. The y-axis shows significantly enriched (A) “Biological Process” (BP) categories, (B) “Molecular function” (MF) categories and (C) “Reactome Gene Sets” associated with the targets; the x-axis shows the enrichment scores of these terms.
Figure 3Target-function network. A functional module is linked to the targets if the target is involved in that biological process or pathway.
The CDOCKER analysis results of genistein and trans-resveratrol at the active site of PPARγ.
| Compound | -CDCOKER Energy (kcal/mol) | -CDCOKER Interaction_Energy (kcal/mol) |
|---|---|---|
| Genistein | 29.4126 | 37.9578 |
| Trans-resveratrol | 25.1709 | 33.4104 |
Figure 4The docking patterns of genistein and trans-resveratrol interact with PPARγ in the active site of PPARγ illustrated by CDOCKER. 3D presentation of interaction between genistein (A) or trans-resveratrol (B) and PPARγ. 2D presentation of interaction between genistein (C) or trans-resveratrol (D) and PPARγ. The red arrows refer to the amino acid residues that interact with genistein and tran-resveratrol in the binding site of PPARγ.
Figure 5Work scheme of network pharmacology approach. PH: pulmonary hypertension; GO: Gene ontology.